Events, By Category and Date:
» Go to news mainMatthew Herder campaigns for increased access to drug‑safety data
Read coverage of this story from Elizabeth Church.
- Halifax professor campaigns for increased access to drug-safety data. Globe & Mail, 22 Dec 2015.
In the following explanatory blog, Matthew Herder issues a call to action directed at physicians, biomedical researchers, health care professionals, civil society, investigative journalists and others to take advantage of a new mechanism in Canadian law that has the potential to open up data about the safety and effectiveness of drugs.
- Enacting pharmaceutical transparency—Who, what, how, when & why. All Trials. 21 Dec 2015.
- Enacting pharmaceutical transparency—Who, what, how, when & why. Impact Ethics . 21 Dec 2015.
Download the provided template letter: it can be used to request from Health Canada access to all unpublished information, including clinical trials and other investigational studies, pertaining to the safety and effectiveness of a given therapeutiic product about which you would be interested to find out more information.
Finally, read Matthew's original article,
- Reinstitutionalizing transparency at Health Canada.Canadian Medical Association Journal [PDF 192 KB - Open Access]. Early release, published at www.cmaj.ca, 22 Dec 2015.
Recent News
- On what basis did Health Canada approve OxyContin in 1996? A retrospective analysis of regulatory data
- Matthew Herder Resigns from Patented Medicine Prices Review Board
- Permissive regulation: A critical review of the regulatory history of buprenorphine formulations in Canada
- Fair pricing of “old” orphan drugs: considerations for Canada’s orphan drug policy
- Podcast or Perish: Episode 040: Françoise Baylis
- Bioethicist Françoise Baylis asks why humans think 'they can just take everything'
- Killam Prize winners discuss research in Canada
- World‑renowned Dalhousie bioethicist and battery pioneer win prestigious Killam Prize